{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:19:39Z","timestamp":1792905579637,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AR070892"],"award-info":[{"award-number":["K24 AR070892"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 GM115458"],"award-info":[{"award-number":["U54 GM115458"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1053\/j.ajkd.2024.04.017","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T19:25:06Z","timestamp":1718825106000},"page":"538-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial"],"prefix":"10.1053","volume":"84","author":[{"given":"Lindsay N.","family":"Helget","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Davis-Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff A.","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Androsenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant R.","family":"England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Palevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ajkd.2024.04.017_bib1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1053\/j.ajkd.2024.04.017_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 Updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2024.04.017_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2458-11-101","article-title":"Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany","volume":"11","author":"Van den Bussche","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1053\/j.ajkd.2024.04.017_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2024.04.017_bib5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","article-title":"Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012","volume":"36","author":"Ramasamy","year":"2013","journal-title":"Drug Saf"},{"issue":"1","key":"10.1053\/j.ajkd.2024.04.017_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2012.04.011","article-title":"Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities","volume":"164","author":"White","year":"2012","journal-title":"Am Heart J"},{"issue":"10264","key":"10.1053\/j.ajkd.2024.04.017_bib7","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2024.04.017_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1053\/j.ajkd.2024.04.017_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","article-title":"Design and rationale for the Veterans Affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d Trial","volume":"68","author":"Timilsina","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"10","key":"10.1053\/j.ajkd.2024.04.017_bib10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2024.04.017_bib11","article-title":"FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat)","year":"2019","journal-title":"FDA Drug Safety Communication"},{"issue":"1","key":"10.1053\/j.ajkd.2024.04.017_bib12","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1053\/j.ajkd.2024.04.017_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5414\/CP203466","article-title":"Comparison of long-term efficacy and renal safety\u00a0of febuxostat and allopurinol in patients with chronic kidney diseases","volume":"58","author":"Yang","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"23","key":"10.1053\/j.ajkd.2024.04.017_bib14","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.04.017_bib15","first-page":"265","article-title":"Febuxostat in the management of gout: a cost-effectiveness analysis","volume":"19","author":"Smolen","year":"2016","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1053\/j.ajkd.2024.04.017_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","article-title":"Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort","volume":"17","author":"Singh","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"10156","key":"10.1053\/j.ajkd.2024.04.017_bib17","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2024.04.017_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bcp.13516","article-title":"The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool","volume":"84","author":"Wright","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.04.017_bib19","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1053\/j.ajkd.2024.04.017_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M21-2347","article-title":"Allopurinol initiation and all-cause mortality among patients with gout and concurrent chronic kidney disease: a population-based cohort study","volume":"175","author":"Wei","year":"2022","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1053\/j.ajkd.2024.04.017_bib21","first-page":"1341","article-title":"Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study","volume":"33","author":"Hunter","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.04.017_bib22","article-title":"Characteristics of acute gout flare in patients initiated on intravenous bumetanide for acute heart failure exacerbation","volume":"12","author":"Jeong","year":"2020","journal-title":"Cureus"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624008357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624008357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:51:57Z","timestamp":1788983517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624008357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0272638624008357"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.04.017","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.","name":"copyright","label":"Copyright"}]}}